Search

Your search keyword '"Jagannath, S"' showing total 30 results
Start Over Author "Jagannath, S" Publisher american society of clinical oncology (asco)
30 results on '"Jagannath, S"'

2. Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study.

Author

Richardson, P. G. G., primary, Moreau, P., additional, Jakubowiak, A. J., additional, Facon, T., additional, Jagannath, S., additional, Vij, R., additional, Reece, D. E., additional, White, D., additional, Raab, M., additional, Benboubker, L., additional, Rossi, J., additional, Tsao, C., additional, Parli, T., additional, Berman, D. M., additional, Singhal, A. K., additional, and Lonial, S., additional

Published
2011
Full Text
View/download PDF

20. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.

Author

Desikan, K R, primary, Barlogie, B, additional, Jagannath, S, additional, Vesole, D H, additional, Siegel, D, additional, Fassas, A, additional, Munshi, N, additional, Singhal, S, additional, Mehta, J, additional, Tindle, S, additional, Nelson, J, additional, Bracy, D, additional, Mattox, S, additional, and Tricot, G, additional

Published
1998
Full Text
View/download PDF

22. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

Author

Gajewski, J L, primary, Phillips, G L, additional, Sobocinski, K A, additional, Armitage, J O, additional, Gale, R P, additional, Champlin, R E, additional, Herzig, R H, additional, Hurd, D D, additional, Jagannath, S, additional, Klein, J P, additional, Lazarus, H M, additional, McCarthy, P L, additional, Pavlovsky, S, additional, Peterson, F B, additional, Rowlings, P A, additional, Russell, J A, additional, Silver, S M, additional, Vose, J M, additional, Wiernik, P H, additional, Bortin, M M, additional, and Horowitz, M M, additional

Published
1996
Full Text
View/download PDF

30. Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

Author

Jean Paul Fermand, Patrizia Tosi, Joan Bladé, Kenneth C. Anderson, Orhan Sezer, Jean Luc Harousseau, Pieter Sonneveld, Ruben Niesvizky, Antonio Palumbo, Bart Barlogie, Meletios A. Dimopoulos, Heinz Ludwig, Raymond L. Comenzo, Brian G.M. Durie, Sundar Jagannath, Asher Chanan-Khan, Michele Cavo, Sergio Giralt, Nelson Leung, Evangelos Terpos, Paul G. Richardson, Jesús F. San Miguel, S. Vincent Rajkumar, Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel J, Radiology & Nuclear Medicine, and Hematology

Subjects
Cancer Research, medicine.medical_specialty, Urology, Renal function, urologic and male genital diseases, Transplantation, Autologous, Nephropathy, Bortezomib, chemistry.chemical_compound, medicine, Humans, Renal Insufficiency, Myeloma cast nephropathy, Melphalan, Multiple myeloma, Lenalidomide, Creatinine, business.industry, Incidence, Hematopoietic Stem Cell Transplantation, Prognosis, medicine.disease, Boronic Acids, Thalidomide, Surgery, Oncology, chemistry, Pyrazines, Multiple Myeloma, business, Glomerular Filtration Rate, Kidney disease, medicine.drug
Abstract

Renal impairment is a common complication of multiple myeloma (MM). The estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula is the recommended method for the assessment of renal function in patients with MM with stabilized serum creatinine. In acute renal injury, the RIFLE (risk, injury, failure, loss and end-stage kidney disease) and Acute Renal Injury Network criteria seem to be appropriate to define the severity of renal impairment. Novel criteria based on eGFR measurements are recommended for the definition of the reversibility of renal impairment. Rapid intervention to reverse renal dysfunction is critical for the management of these patients, especially for those with light chain cast nephropathy. Bortezomib with high-dose dexamethasone is considered as the treatment of choice for such patients. There is limited experience with thalidomide in patients with myeloma with renal impairment. Thus, thalidomide can be carefully administered, mainly in the context of well-designed clinical trials, to evaluate if it can improve the rapidity and probability of response that is produced by the combination with bortezomib and high-dose dexamethasone. Lenalidomide is effective in this setting and can reverse renal insufficiency in a significant subset of patients, when it is given at reduced doses, according to renal function. The role of plasma exchange in patients with suspected light chain cast nephropathy and renal impairment is controversial. High-dose melphalan (140 mg/m(2)) and autologous stem-cell transplantation should be limited to younger patients with chemosensitive disease. J Clin Oncol 28:4976-4984. (C) 2010 by American Society of Clinical Oncology

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results